Free tool
FAERS Monitor: Jalyn
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022460 or its brand name (Jalyn, Dutasteride, Tamsulosin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,046
Serious
405
39% of reports
Hospitalization
191
Death reported
58
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective90
- dizziness72
- rash43
- diarrhoea39
- fatigue39
- dyspnoea35
- fall32
- erectile dysfunction30
- pruritus29
- headache25
- hypotension25
- asthenia23
- pneumonia22
- blood pressure decreased18
- constipation18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 12 |
| 2011 | 200 |
| 2012 | 187 |
| 2013 | 109 |
| 2014 | 105 |
| 2015 | 111 |
| 2016 | 96 |
| 2017 | 39 |
| 2018 | 51 |
| 2019 | 39 |
| 2020 | 32 |
| 2021 | 17 |
| 2022 | 12 |
| 2023 | 5 |
| 2024 | 14 |
| 2025 | 6 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,113 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| erectile dysfunctionSignal | 30 | 23.5 | 16.5 | 625 |
| blood pressure decreasedSignal | 18 | 5.4 | 3.4 | 61 |
| dizzinessSignal | 72 | 2.9 | 2.3 | 90 |
| hypotensionSignal | 25 | 2.5 | 1.7 | 21 |
| rash | 43 | 2.0 | 1.5 | 20 |
| fall | 32 | 1.9 | 1.4 | 14 |
| constipation | 18 | 1.7 | 1.0 | 4 |
| pruritus | 29 | 1.5 | 1.1 | 5 |
| drug ineffective | 90 | 1.4 | 1.1 | 9 |
| pneumonia | 22 | 1.4 | 0.9 | 2 |
| dyspnoea | 35 | 1.2 | 0.9 | 1 |
| asthenia | 23 | 1.2 | 0.8 | 1 |
| diarrhoea | 39 | 1.2 | 0.9 | 1 |
| fatigue | 39 | 1.0 | 0.7 | 0 |
| headache | 25 | 0.8 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.